• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.唾液酸酶NEU1与伴侣蛋白保护蛋白/组织蛋白酶A的异源二聚化可防止其过早寡聚化。
J Biol Chem. 2009 Oct 9;284(41):28430-28441. doi: 10.1074/jbc.M109.031419. Epub 2009 Aug 7.
2
[Orientation of three lysosomal enzymes in the mouse inner ear and hearing loss in enzyme gene deficiency].[小鼠内耳中三种溶酶体酶的定位及酶基因缺陷导致的听力损失]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Feb;31(1):79-84.
3
New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.PPBG基因中的新突变导致PPCA蛋白缺失,这会影响β-半乳糖苷酶/神经氨酸酶复合物和EBP受体的水平。
Mol Genet Metab. 2004 May;82(1):48-55. doi: 10.1016/j.ymgme.2004.02.007.
4
Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.通过正常基因转移和酶替代消除患有唾液酸沉积症和半乳糖唾液酸沉积症的成纤维细胞中的异常唾液酸糖蛋白。
Glycobiology. 2006 Apr;16(4):271-80. doi: 10.1093/glycob/cwj069. Epub 2005 Dec 15.
5
The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.NEU1选择性唾液酸酶抑制剂C9-丁基酰胺-DANA可在体外人肺组织及体内小鼠肺组织中阻断唾液酸酶活性和NEU1介导的生物活性。
Glycobiology. 2016 Aug;26(8):834-49. doi: 10.1093/glycob/cww060. Epub 2016 May 25.
6
Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.重组人β-半乳糖苷酶间歇性酶替代疗法可预防神经氨酸酶 1 缺乏症。
J Biol Chem. 2020 Sep 25;295(39):13556-13569. doi: 10.1074/jbc.RA119.010794. Epub 2020 Jul 28.
7
Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease.糖脂和糖蛋白贮积病发病机制的分子机制。
Biochem Soc Trans. 2010 Dec;38(6):1453-7. doi: 10.1042/BST0381453.
8
Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.在I型唾液酸贮积症新小鼠模型中采用重组腺相关病毒 - PPCA进行伴侣介导的基因治疗。
Biochim Biophys Acta. 2013 Oct;1832(10):1784-92. doi: 10.1016/j.bbadis.2013.06.002. Epub 2013 Jun 12.
9
Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.来自溶酶体β-半乳糖苷酶、保护蛋白/组织蛋白酶A和神经氨酸酶-1缺乏症患者的培养真皮成纤维细胞中的弹性生成。
J Med Invest. 2006 Feb;53(1-2):103-12. doi: 10.2152/jmi.53.103.
10
Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1.溶酶体羧肽酶(组织蛋白酶)A的酶活性是正常弹性纤维形成和内皮素-1失活所必需的。
Circulation. 2008 Apr 15;117(15):1973-81. doi: 10.1161/CIRCULATIONAHA.107.733212. Epub 2008 Apr 7.

引用本文的文献

1
Type I Sialidosis in a Chinese family: a case report and literature review.一个中国家庭中的I型唾液酸沉积症:病例报告及文献综述
Acta Epileptol. 2025 Jun 4;7(1):34. doi: 10.1186/s42494-025-00225-3.
2
Neu1 deficiency and fibrotic lymph node microenvironment lead to imbalance in M1/M2 macrophage polarization.Neu1 缺乏和纤维化的淋巴结微环境导致 M1/M2 巨噬细胞极化失衡。
Front Immunol. 2024 Sep 13;15:1462853. doi: 10.3389/fimmu.2024.1462853. eCollection 2024.
3
AAV-mediated gene therapy for sialidosis.腺相关病毒介导的唾液酸贮积症基因治疗。
Mol Ther. 2024 Jul 3;32(7):2094-2112. doi: 10.1016/j.ymthe.2024.05.029. Epub 2024 May 25.
4
Gene therapy corrects the neurological deficits of mice with sialidosis.基因疗法纠正黏脂贮积症小鼠的神经功能缺陷。
Gene Ther. 2024 May;31(5-6):263-272. doi: 10.1038/s41434-024-00443-3. Epub 2024 Feb 7.
5
Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.溶酶体唾液酸酶 NEU1、其细胞内特性、缺乏及其作为治疗剂的应用。
Glycoconj J. 2023 Dec;40(6):611-619. doi: 10.1007/s10719-023-10135-6. Epub 2023 Dec 26.
6
Structure of the immunoregulatory sialidase NEU1.免疫调节神经氨酸酶 NEU1 的结构。
Sci Adv. 2023 May 19;9(20):eadf8169. doi: 10.1126/sciadv.adf8169.
7
Sialidase Inhibitors with Different Mechanisms.唾液酸酶抑制剂的不同作用机制。
J Med Chem. 2022 Oct 27;65(20):13574-13593. doi: 10.1021/acs.jmedchem.2c01258. Epub 2022 Oct 17.
8
Neuraminidase-1: A Sialidase Involved in the Development of Cancers and Metabolic Diseases.神经氨酸酶-1:一种参与癌症和代谢性疾病发展的唾液酸酶
Cancers (Basel). 2022 Oct 5;14(19):4868. doi: 10.3390/cancers14194868.
9
Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis.用重组β-半乳糖苷酶-凝集素融合物进行临床前酶替代治疗,以实现中枢神经系统递送和治疗 GM1-神经节苷脂病。
Cells. 2022 Aug 19;11(16):2579. doi: 10.3390/cells11162579.
10
Neuraminidases-Key Players in the Inflammatory Response after Pathophysiological Cardiac Stress and Potential New Therapeutic Targets in Cardiac Disease.神经氨酸酶——病理生理心脏应激后炎症反应的关键参与者及心脏病潜在的新治疗靶点
Biology (Basel). 2022 Aug 17;11(8):1229. doi: 10.3390/biology11081229.

本文引用的文献

1
Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.保护蛋白/组织蛋白酶A挽救神经氨酸酶-1中的N-糖基化缺陷。
Biochim Biophys Acta. 2009 Apr;1790(4):275-82. doi: 10.1016/j.bbagen.2009.01.006.
2
Neuraminidase 1 is a negative regulator of lysosomal exocytosis.神经氨酸酶1是溶酶体胞吐作用的负调节因子。
Dev Cell. 2008 Jul;15(1):74-86. doi: 10.1016/j.devcel.2008.05.005.
3
Protein structure modeling with MODELLER.使用MODELLER进行蛋白质结构建模。
Methods Mol Biol. 2008;426:145-59. doi: 10.1007/978-1-60327-058-8_8.
4
Characterizing protein-protein interactions by sedimentation velocity analytical ultracentrifugation.通过沉降速度分析型超速离心法表征蛋白质-蛋白质相互作用。
Curr Protoc Immunol. 2008 May;Chapter 18:18.15.1-18.15.39. doi: 10.1002/0471142735.im1815s81.
5
Incorporating biochemical information and backbone flexibility in RosettaDock for CAPRI rounds 6-12.在RosettaDock中纳入生化信息和主链灵活性用于CAPRI第6 - 12轮。
Proteins. 2007 Dec 1;69(4):793-800. doi: 10.1002/prot.21731.
6
GRAMM-X public web server for protein-protein docking.用于蛋白质-蛋白质对接的GRAMM-X公共网络服务器。
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W310-4. doi: 10.1093/nar/gkl206.
7
Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation.通过沉降速度分析型超速离心法测定的大分子尺寸和形状分布
Biophys J. 2006 Jun 15;90(12):4651-61. doi: 10.1529/biophysj.106.081372. Epub 2006 Mar 24.
8
Development and testing of an automated approach to protein docking.蛋白质对接自动化方法的开发与测试
Proteins. 2005 Aug 1;60(2):296-301. doi: 10.1002/prot.20573.
9
Short-term, high dose enzyme replacement therapy in sialidosis mice.对唾液酸沉积症小鼠进行短期高剂量酶替代疗法。
Mol Genet Metab. 2005 Jul;85(3):181-9. doi: 10.1016/j.ymgme.2005.03.007. Epub 2005 Apr 25.
10
Evidence for mitochondrial localization of a novel human sialidase (NEU4).一种新型人类唾液酸酶(NEU4)的线粒体定位证据。
Biochem J. 2005 Aug 15;390(Pt 1):85-93. doi: 10.1042/BJ20050017.

唾液酸酶NEU1与伴侣蛋白保护蛋白/组织蛋白酶A的异源二聚化可防止其过早寡聚化。

Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.

作者信息

Bonten Erik J, Campos Yvan, Zaitsev Viateslav, Nourse Amanda, Waddell Brett, Lewis William, Taylor Garry, d'Azzo Alessandra

机构信息

Department of Genetics and Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794.

Department of Genetics and Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794.

出版信息

J Biol Chem. 2009 Oct 9;284(41):28430-28441. doi: 10.1074/jbc.M109.031419. Epub 2009 Aug 7.

DOI:10.1074/jbc.M109.031419
PMID:19666471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2788892/
Abstract

Lysosomal neuraminidase-1 (NEU1) forms a multienzyme complex with beta-galactosidase and protective protein/cathepsin A (PPCA). Because of its association with PPCA, which acts as a molecular chaperone, NEU1 is transported to the lysosomal compartment, catalytically activated, and stabilized. However, the mode(s) of association between these two proteins both en route to the lysosome and in the multienzyme complex has remained elusive. Here, we have analyzed the hydrodynamic properties of PPCA, NEU1, and a complex of the two proteins and identified multiple binding sites on both proteins. One of these sites on NEU1 that is involved in binding to PPCA can also bind to other NEU1 molecules, albeit with lower affinity. Therefore, in the absence of PPCA, as in the lysosomal storage disease galactosialidosis, NEU1 self-associates into chain-like oligomers. Binding of PPCA can reverse self-association of NEU1 by causing the disassembly of NEU1-oligomers and the formation of a PPCA-NEU1 heterodimeric complex. The identification of binding sites between the two proteins allowed us to create innovative structural models of the NEU1 oligomer and the PPCA-NEU1 heterodimeric complex. The proposed mechanism of interaction between NEU1 and its accessory protein PPCA provides a rationale for the secondary deficiency of NEU1 in galactosialidosis.

摘要

溶酶体神经氨酸酶-1(NEU1)与β-半乳糖苷酶和保护蛋白/组织蛋白酶A(PPCA)形成多酶复合物。由于其与作为分子伴侣的PPCA相关联,NEU1被转运至溶酶体区室,被催化激活并得以稳定。然而,这两种蛋白质在转运至溶酶体的途中以及在多酶复合物中的结合模式仍不清楚。在此,我们分析了PPCA、NEU1以及这两种蛋白质复合物的流体动力学性质,并确定了这两种蛋白质上的多个结合位点。NEU1上参与与PPCA结合的其中一个位点也能与其他NEU1分子结合,尽管亲和力较低。因此,在不存在PPCA的情况下,如在溶酶体贮积病半乳糖唾液酸贮积症中,NEU1会自组装成链状寡聚体。PPCA的结合可通过导致NEU1寡聚体的解体以及形成PPCA-NEU1异二聚体复合物来逆转NEU1的自组装。这两种蛋白质之间结合位点的确定使我们能够创建NEU1寡聚体和PPCA-NEU1异二聚体复合物的创新结构模型。所提出的NEU1与其辅助蛋白PPCA之间的相互作用机制为半乳糖唾液酸贮积症中NEU1的继发性缺陷提供了理论依据。